- Home
- NBH vs CRMD Comparison
NBH vs CRMD Comparison
Compare NBH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBH | CRMD |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 943.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NBH | CRMD |
|---|---|---|
| Price | $10.15 | $12.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 85.9K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.12 | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | $87.04 | ★ $5.41 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $8.75 | $5.60 |
| 52 Week High | $11.01 | $17.43 |
Technical Indicators
Market Signals| Indicator | NBH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 63.43 |
| Support Level | $10.08 | $11.78 |
| Resistance Level | $10.28 | $12.51 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 28.00 | 85.18 |
Price Performance
Historical ComparisonAbout NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.